MnDPDP for MR imaging of the liver

Abstract

Purpose:To evaluate the diagnostic efficacy and safety of MnDPDP (Teslascan) in enhanced MR imaging.Material and Methods: In 2 multiple independent trials in Europe 624 patients weregiven MnDPDP intravenously at 5 pmolkg b.w. Patients underwent an unenhanced MR examination comprising T1 -weighted spin-echo and breath-hold gradient-echo sequences and a T2-weighted spin-echo sequence. The T I sequences were repeated after the administration of MnDPDP. In a subgroup of 137 patients the results of the enhanced MR images were compared with the results of contrast-enhanced CT (CECT) images. Results: For both types of T1-weighted sequences and when evaluating the maximum numbers of lesions seen in all imaging sequences, the total numbers of lesions seen were significantly higher in the MnDPDP-enhanced images than in the unenhanced images (p=0.0005 and p=O.OOOl , respectively). The investigators considered the enhanced images to contain "other additional information not found in the unenhanced images" in 279 (45%) of the 621 patients examined. The MnDPDP-enhanced images were also superior to the CECT images in the detection of lesions @=0.02). Adverse events were reported by 46 patients (7%) and infusion-associated discomfort by 26 (4%). Heart rates and systolic and diastolic blood pressures showed no clinically significant changes from baseline as a result of the administration of the contrast medium.Conclusion: MnDPDP was shown to be effective and safe in enhanced MR imaging of the liver. Mangafodipir FAX +47-23 18 60 00.

Activatable Core–Shell Metallofullerene: An Efficient Nanoplatform for Bimodal Sensing of Glutathione

“…This process can result in significant enhancement of fluorescence and simultaneously MR signals. This resultant MR signal enhancement is superior to those reported in many manganese-based contrast systems by release of free Mn 2+ ions. ,− To overcome reported adverse effects from over dosage or leakage of Mn (e.g., cardiotoxicity, nausea, headache, and pruritus), − the incorporation of fullerenes could provide high-relaxivity MRI contrast at reduced dosage levels and significantly suppress the release of free Mn 2+ ions, and both approaches have resulted in reduced toxicity.…”

Macromolecules, Dendrimers, and Nanomaterials in Magnetic Resonance Imaging: The Interplay between Size, Function, and Pharmacokinetics

“…30 In a European phase III clinical trial, adverse events, such as nausea, headache, and pruritus, were observed in 7% of the 624 patients. 478,479 Transient decreases in alkaline phosphatase levels and sensations of heat and flushing with high injection rates most likely related to peripheral vasodilatation have also been reported.…”

“…T 1 liver enhancement after intravenous infusion begins early, 1−2 min postinjection, maximizes within 5−10 min, and persists for several hours, allowing flexibility for patient scheduling when compared to Gd 3+ chelates. No longer on the market, for human clinical imaging to detect hepatic lesions, the approved dosage of Mn-DPDP was 5 μmol/kg, and approximately 15% was eliminated in the urine by 24 h postinjection and 59% in the feces by 5 days . In a European phase III clinical trial, adverse events, such as nausea, headache, and pruritus, were observed in 7% of the 624 patients. , Transient decreases in alkaline phosphatase levels and sensations of heat and flushing with high injection rates most likely related to peripheral vasodilatation have also been reported.…”